(美国商业资讯)-- 百奥赛图（HKEX：02315），一家创新技术驱动新药研发的国际性生物技术公司，今日宣布，其临床前业务板块实现全面升级，涵盖靶点人源化小鼠、免疫系统人源化小鼠、转基因小鼠、免疫缺陷鼠等模式动物产品，并提供覆盖药效学、PK/PD、生物标志物、非GLP毒理学评估在内的一体化临床前产品及服务，为全球药物研发提供更精准、高效的解决方案。同时，公司全新官网 https://...
Source Link(美国商业资讯)-- 百奥赛图（HKEX：02315），一家创新技术驱动新药研发的国际性生物技术公司，今日宣布，其临床前业务板块实现全面升级，涵盖靶点人源化小鼠、免疫系统人源化小鼠、转基因小鼠、免疫缺陷鼠等模式动物产品，并提供覆盖药效学、PK/PD、生物标志物、非GLP毒理学评估在内的一体化临床前产品及服务，为全球药物研发提供更精准、高效的解决方案。同时，公司全新官网 https://...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.